Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) EPS (Basic) (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed EPS (Basic) for 14 consecutive years, with -$0.45 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 2.17% to -$0.45 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.9 through Dec 2025, down 28.38% year-over-year, with the annual reading at -$1.67 for FY2025, 9.87% down from the prior year.
  • EPS (Basic) hit -$0.45 in Q4 2025 for Vistagen Therapeutics, up from -$0.54 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.2 in Q1 2021 to a low of -$2.87 in Q2 2022.
  • Historically, EPS (Basic) has averaged -$1.06 across 5 years, with a median of -$0.6 in 2023.
  • Biggest five-year swings in EPS (Basic): crashed 3980.0% in 2021 and later skyrocketed 85.38% in 2024.
  • Year by year, EPS (Basic) stood at -$1.59 in 2021, then rose by 10.69% to -$1.42 in 2022, then surged by 84.51% to -$0.22 in 2023, then crashed by 109.09% to -$0.46 in 2024, then increased by 2.17% to -$0.45 in 2025.
  • Business Quant data shows EPS (Basic) for VTGN at -$0.45 in Q4 2025, -$0.54 in Q3 2025, and -$0.47 in Q2 2025.